Abbisko Therapeutics Announces IND Clearance from the CDE for ABSK061, a Highly Selective FGFR2/3 Inhibitor, for the Treatment of Achondroplasia
Abbisko Therapeutics Co., Ltd. has announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has cleared the IND application for ABSK061, a highly…